AstraZeneca Worries Complicate Bid to Vaccinate the World Bloomberg 2 hrs ago James Paton, Tim Loh and Todd Gillespie
(Bloomberg) Growing worries that AstraZeneca Plc’s Covid-19 vaccine causes rare blood clots could hinder immunization campaigns across the world, from London to Seoul.
Reviews by U.K. and European Union regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on in a bid to end the pandemic.
Safety concerns could shake confidence in the injection, even though regulators reiterated that its benefits outweigh the risks. Many regions are turning their attention to vaccines from Johnson & Johnson and developers in China, Russia and elsewhere, but they’re still in a difficult position with demand for doses far outstripping supply.
AstraZeneca Blood Clot Worries Could Set Back Vaccinations Worldwide dailyexcelsior.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyexcelsior.com Daily Mail and Mail on Sunday newspapers.
Growing worries that AstraZeneca Plc’s Covid-19 vaccine causes rare blood clots could hinder immunization campaigns across the world, from London to Seoul. Reviews by UK and European Union regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on in a bid to end the pandemic. Safety concerns could shake confidence in the injection, even though regulators reiterated that its benefits outweigh the risks. Many regions are turning their attention to vaccines from Johnson & Johnson and developers in China, Russia and elsewhere, but they’re still in a difficult position with demand for doses far outstripping supply.
Apr 8, 2021, 1:00 AM – Updated on Apr 8, 2021, 11:22 AM
Word Count: 974
Reviews by U.K. and European Union regulators finding potential links to the unusual side effects are another blow for the shot, a cheaper and easier-to-deploy product that many nations are counting on in a bid to end the pandemic.
Safety concerns could shake confidence in the injection, even though regulators reiterated that its benefits outweigh the risks. Many regions are turning their attention to vaccines from Johnson & Johnson and developers in China, Russia and elsewhere, but they’re still in a difficult position with demand for doses far outstripping supply.
“Better Astra than nothing,” said Michael Kinch, a drug development expert and associate vice chancellor at Washington University in St. Louis. “In an under-vaccinated country, I think you have no choice but to take it.”
AstraZeneca clot worries complicate bid to vaccinate the world japantimes.co.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantimes.co.jp Daily Mail and Mail on Sunday newspapers.